Zeo ScientifiX, Inc. (ZEOX) stock
ZEOXOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
$0.91+0.00 (+0.15%)
Close on Oct 19, 2026Market cap $7.08MP/E –Yield –
Zeo ScientifiX gross margin
Gross margin is gross profit as a percentage of revenue.
Zeo ScientifiX's gross margin for the twelve months ending Apr 30, 2026 was 81.5%. For fiscal 2025 it was 82.1%, against 81.7% the year before. The highest annual figure on record is 90.2% in fiscal 2021.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 82.1% | +0.4 |
| FY2024 | Oct 31, 2024 | 81.7% | −7.1 |
| FY2023 | Oct 31, 2023 | 88.9% | +0.5 |
| FY2022 | Oct 31, 2022 | 88.4% | −1.8 |
| FY2021 | Oct 31, 2021 | 90.2% | +3.3 |
| FY2020 | Oct 31, 2020 | 87.0% | +4.6 |
| FY2019 | Oct 31, 2019 | 82.3% | +4.0 |
| FY2018 | Oct 31, 2018 | 78.3% | +6.5 |
| FY2017 | Oct 31, 2017 | 71.8% | +22.9 |
| FY2016 | Oct 31, 2016 | 48.9% | −17.6 |
| FY2015 | Oct 31, 2015 | 66.5% | +7.3 |
| FY2014 | Oct 31, 2014 | 59.2% | +12.8 |
| FY2013 | Oct 31, 2013 | 46.4% | +16.6 |
| FY2012 | Oct 31, 2012 | 29.9% | −9.3 |
| FY2011 | Oct 31, 2011 | 39.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | 79.6% | +1.9 |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | 80.6% | −1.9 |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | 84.5% | +9.6 |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | 82.5% | −3.7 |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | 77.7% | −12.9 |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | 82.5% | −4.3 |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | 74.9% | −6.5 |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | 86.2% | −1.6 |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | 90.6% | −2.1 |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | 86.7% | −3.9 |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | 81.3% | −12.2 |
| Q3 FY2022CQ2 2022 | Jul 31, 2022 | 87.8% | −2.2 |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | 92.7% | +3.0 |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | 90.7% | +3.8 |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | 93.6% | +9.6 |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | 90.1% | +4.4 |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | 89.8% | +7.9 |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | 86.8% | +0.8 |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | 84.0% | +12.6 |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | 85.7% | +4.6 |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | 81.9% | +4.0 |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | 86.1% | +4.9 |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | 71.4% | −1.6 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | 81.1% | +3.9 |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | 77.9% | +14.9 |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | 81.1% | −18.9 |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | 73.0% | +114.2 |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | 77.2% | +84.3 |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | 63.0% | −28.5 |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | 100.0% | +28.1 |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -41.2% | −111.5 |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -7.1% | −60.2 |
| Q2 FY2016CQ1 2016 | Apr 30, 2016 | 91.5% | – |
| Q1 FY2016CQ4 2015 | Jan 31, 2016 | 71.9% | – |
| Q4 FY2015CQ3 2015 | Oct 31, 2015 | 70.2% | – |
| Q3 FY2015CQ2 2015 | Jul 31, 2015 | 53.1% | – |
See a number that looks wrong?